Clinical Trial Detail

NCT ID NCT02098538
Title Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

adenoid cystic carcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.